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Glucose transporter 1 critically controls
microglial activation through facilitating
glycolysis
Luxi Wang†, Sofia Pavlou†, Xuan Du, Mohajeet Bhuckory, Heping Xu* and Mei Chen*
Abstract
Background: Uncontrolled microglial activation contributes to the pathogenesis of various neurodegenerative
diseases. Previous studies have shown that proinflammatory microglia are powered by glycolysis, which relays on
high levels of glucose uptake. This study aimed to understand how glucose uptake is facilitated in active microglia
and whether microglial activation can be controlled by restricting glucose uptake.
Methods: Primary murine brain microglia, BV2 cells and the newly established microglial cell line B6M7 were
treated with LPS (100 ng/ml) + IFNγ (100 ng/ml) or IL-4 (20 ng/ml) for 24 h. The expression of glucose transporters
(GLUTs) was examined by PCR and Western blot. Glucose uptake by microglia was inhibited using the GLUT1-
specific inhibitor STF31. The metabolic profiles were tested using the Glycolysis Stress Test and Mito Stress Test Kits
using the Seahorse XFe96 Analyser. Inflammatory gene expression was examined by real-time RT-PCR and protein
secretion by cytokine beads array. The effect of STF31 on microglial activation and neurodegeneraion was further
tested in a mouse model of light-induced retinal degeneration.
Results: The mRNA and protein of GLUT1, 3, 4, 5, 6, 8, 9, 10, 12, and 13 were detected in microglia. The expression
level of GLUT1 was the highest among all GLUTs detected. LPS + IFNγ treatment further increased GLUT1
expression. STF31 dose-dependently reduced glucose uptake and suppressed Extracellular Acidification Rate (ECAR)
in naïve, M(LPS + IFNγ) and M(IL-4) microglia. The treatment also prevented the upregulation of inflammatory
cytokines including TNFα, IL-1β, IL-6, and CCL2 in M(LPS + IFNγ) microglia. Interestingly, the Oxygen Consumption
Rates (OCR) was increased in M(LPS + IFNγ) microglia but reduced in M(IL-4) microglia by STF31 treatment.
Intraperitoneal injection of STF31 reduced light-induced microglial activation and retinal degeneration.
Conclusion: Glucose uptake in microglia is facilitated predominately by GLUT1, particularly under inflammatory
conditions. Targeting GLUT1 could be an effective approach to control neuroinflammation.
Keywords: Neuroinflammation, Microglia, Glucose metabolism, Retinal degeneration
Background
Microglia are resident macrophages of the central
nervous system (CNS) including the neuronal retina [1, 2].
As innate immune cells, microglia can initiate immune
protection under pathophysiological conditions to remove
metabolic wastes, cellular debris and pathogens [2–4].
Under physiological conditions, the debris in the CNS
microenvironment is largely derived from active neurons,
including apoptotic bodies and synaptic debris [5].
Microglia are actively involved in synaptic pruning
and synapse maturation [6], therefore play an import-
ant role in the regulation of synaptic plasticity [7, 8].
During infection, microglia can phagocytize pathogens
and remove dead cells to maintain homeostasis [9].
Uncontrolled microglial activation has been implicated
in neurodegenerative diseases such as Huntington
disease, multiple sclerosis, Alzheimer’s disease [10],
and retinal degeneration [2].
A dynamic cell body and flexibility to rapid change
shape are essential for microglia to carry out their
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protective roles. The protrusions of “resting” microglia
are continuously moving around, scanning the CNS
[11, 12]. After activation, microglia rapidly extend
processes towards the damaged site and retract pro-
cesses facing the other direction [13]. The processes
are employed to phagocytize cellular debris and dam-
aged neurons [14]. Once engaged with pathogens,
they become fully activated, obtain an “ameboid”
shape and can move around rapidly. In addition,
microglia release various cytokines and chemokines,
and can proliferate in situ in response to increased
demand in immune protection [15]. Morphogenesis,
phagocytosis, and migration require dynamic
reorganization of the actin cytoskeleton, for which
vast amount of energy in the form of adenosine tri-
phosphate (ATP) are necessary [16]; whereas, prolifer-
ation and the production of inflammatory mediators
need essential “building materials” such as amino
acids, nucleotides, and fatty acids. How microglia
meet their metabolic demands is not fully understood.
Glucose, amino acids and fatty acids are the three
main energy substrates. Each cell type has its own
unique metabolic profile and is fueled by specific
energy substrates under physiological conditions, and
changes in cellular activity can induce a switch of this
metabolic profile. A previous study using RNA-se-
quencing technique has shown that microglia express
transporters for all these substrates, indicating a flex-
ible use of available energy resources [17]. However,
which metabolic pathway dominates the energy re-
source in microglia under pathophysiological condi-
tions remains unknown.
Recent studies have shown that LPS-stimulated
inflammatory microglia switch from mitochondrial
oxidative phosphorylation (OXPHOX) in resting
conditions to anaerobic glycolysis [18], a phenomenon
that is similar to active macrophages [19]. The mam-
malian brain utilizes glucose as its main source of en-
ergy [20], and the majority of CNS glucose is
consumed by neurons through the glucose transporter
3 (GLUT3) [20]. During CNS inflammation, the high
level of glycolysis in active microglia not only sup-
ports the production of toxic inflammatory mediators,
but also consumes vast amount of glucose that is des-
perately needed by neurons. Further understanding
the metabolic pathways of active microglia will be im-
portant to better control neuroinflammation and im-
prove the management of neurodegeneration.
In this study, we show that microglia express high
levels of glucose transporter 1 (GLUT1), which critically
controls glucose uptake under pathophysiological
conditions. Blocking GLUT1 suppressed microglial
activation and reduced neurodegeneration in a mouse
model of light-induced retinal degeneration.
Materials and methods
Animals
Four-week old wild-type C57BL/6 J mice were used for
primary microglial culture. Twelve-week old C57BL/6J
and CX3CR1gfp/+ mice (C57BL/6 J background) were used
in the light-induced retinal degeneration study. All mice
were maintained in the Biological Services Unit of Queen’s
University Belfast (QUB) with 12-h light-dark cycle. All
procedures were conducted under the regulation of the
UK Home Office Animals (Scientific Procedures) Act
1986, and were in compliance with the Association for
Research in Vision and Ophthalmology Statement for the
Use of Animals in Ophthalmology and Vision Research.
The procedures were approved by the Animal Welfare &
Ethical Review Body of QUB.
Microglial culture
BV2 cells were cultured in DMEM (Gibco, BRL, Paisley,
UK) supplemented with 10% fetal calf serum (FCS) and
100 μg/ml primocin (Invivogen, San Diego, California,
USA). Primary murine microglia were isolated and cul-
tured from C57BL/6 J mice using a previously reported
protocol with slight modifications [21]. Briefly, brain tis-
sues were dissected from 4-week old mice and digested
with 0.05% trypsin at 37 °C for 10 min. The single cell
suspension was cultured in DMEM with 10% FCS and
20% L929 conditioned media [22]. After 5 days, floating
cells were removed, and attached cells (microglia) were
cultured for a further 5 days. The cells were passaged
once reached confluency, and cells from passages 2–5
were used in the study. Immunocytochemistry showed
that > 95% of cells were CD11b+F4/80+. During primary
microglia culture, one cell line was spontaneously im-
mortalized and subsequently cloned. One of the clones,
B6M7 was also used in this study.
Cell stimulation
BV2, B6M7 and primary microglia were treated with LPS
(100 ng/ml, E. coli, serotype 055: B5) + IFNγ (100 ng/ml)
or IL-4 (20 ng/ml) (all from Sigma-Aldrich, Dorset, UK)
for 24 h. The cells were termed as M(LPS + IFNγ) and
M(IL-4) respectively. The supernatants were collected for
cytokine/chemokine measurements (see below). Cells
were collected for gene and protein expression studies.
Quantitative real-time reverse transcription PCR
Total RNA was extracted from BV2, B6M7 or primary
microglia using TRI Reagent (Sigma-Aldrich). cDNA
synthesis was performed with a random primer using the
SuperScript™ II Reverse Transcriptase kit (Invitrogen) in a
reaction of 1 μg of total RNA per reaction. Murine mRNA
expression levels were quantified by qRT-PCR using SYBR
Green I Master and the LightCycler 480 system (Roche
Diagnostics GmbH, Mannheim, Germany) with specific
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primers (Table 1). GLUT1–13 primers were purchased
from Primer Design (Southampton, UK). Other primers
were self-designed using the Primer-Blast (https://
www.ncbi.nlm.nih.gov/tools/primer-blast/) and purchased
from Integrated DNA Technologies, Inc. (Leuven,
Belgium).
Cytokine and chemokine measurement
Cytokines and chemokines including MCP-1/CCL2,
IL-6, TNF-α and CCL5/RANTES in supernatants were
measured by Cytometric Bead Array (CBA) assay (BD
Biosciences, Oxford, UK) according to the manufac-
turer’s instructions. Briefly, 25 μl sample and 25 μl cap-
ture beads were mixed and incubated for 1 h followed by
the addition of 25 μl PE-conjugated detection reagent for
a further hour. Samples were washed and were acquired
using FACS Canto II (BD Biosciences). Data were ana-
lyzed using FlowJo software. The fold change in cytokine
levels relative to control groups was calculated.
Produciton of Reactive Oxygen Species (ROS)
Intracellular ROS was measured using CellROX Green
kit; mitochondrial ROS was measured using MitoSOX
(MitoSOX Red), and nitrite oxide (NO) concentration in
the supernatants was measured using the Griess Reagent
Kit according to the manufacturers’ instructions. All re-
agents were from Thermo Fisher Scientific (Winsford,
UK). Fluorescent signaling for CellROX and MitoSOX
and absorbance for NO was immediately measured
using FLUOstar Omega plate reader (BMG Labtech Ltd.,
Bucks, UK).
Glucose uptake
Cells were cultured in a 96-well plate until 80% conflu-
ence. Prior to the assay, cells were washed with PBS
twice and incubated in serum-free DMEM overnight.
Glucose uptake by different microglial cells was mea-
sured using the Glucose Uptake Assay Kit (ab136955,
Abcam, Cambridge, UK) following manufacturer’s
instructions. Glucose levels were was quantified using
the FLUOstar Omega plate reader (BMG Labtech).
Cell bioenergy tests
BV2 and B6M7 cells were seeded in XFe 96-well micro-
plates (6000 cells/well) (Agilent Technologies, Sana
Clara, USA) with/without 5 μM STF31 (C23H25N3O3S,
Millipore, Watford, UK) for 24 h, followed by LPS +
IFNγ (both 100 ng/ml) or IL-4 (20 ng/ml) stimulation
for a further 24 h. Cells were washed and incubated in
base medium (Agilent Technologies) at 37 °C for 1 h.
Extracellular Acidification Rate (ECAR) and Oxygen
Consumption Rate (OCR) were measured in real-time
with Glycolysis Stress Test Kit and Mito Stress Test Kit
respectively using the Seahorse XFe96 Analyser (Agilent
Technologies) following manufacturer’s instructions.
Data were normalized by cell numbers that was mea-
sured by the YO-PRO®-1 Assay (Thermo Fisher
Scientific).
GLUT1 inhibition by STF31 in vitro
Microglial cells were seeded into 96-well plates and
treated with different concentrations of STF31 (Millipore)
ranging from 0.01 μM to 50 μM for 24 h to 48 h. Cells
were further processed for glucose uptake assay (see
Table 1 Primers used for qRT-PCR
Targets Annealing
temperature (°C)
Sequences (5′ - 3′) F: forward R: reverse
β-actin 58 F CCTTCCTTCTTGGGTATG
R TGTAAAACGCAGCTCAGTAA
GLUT1 60 F CCCCGTCCTGCTGCTATTG
R GCACCGTGAAGATGATGAAGAC
GLUT3 60 F TGTCCAGGAACCGATCTATGC
R CCACCAGGAACAGAGAAACTAC
GLUT4 60 F CCAGTATGTTGCGGATGCTAT
R TTTTAGGAAGGTGAAGATGAAGAAG
GLUT5 60 F ACCTCAGCGCAGGCGTGAAA
R AGCAGGCTATGAGGCAGGTGGA
GLUT6 60 F CGTCCAGTTTGTGCCAAGG
R CAGCAGGGGTATCAGGGTAAG
GLUT8 60 F GCTCACCGCTGCCTTCTG
R CGAAATGGGCTGTGACTTGTT
GLUT9 60 F ACTATGTGGACTCAATGCGATCT
R TCAATGACCAAGCCAGAGAAGA
GLUT10 60 F CTCTGTGGCGTTCATCAAGTG
R ACGAGGAAGGCGGAGACT
GLUT12 60 F TGGCAGCAAAACCTTCCTCT
R AGGGACTGGTTAAGAAGACTATGG
GLUT13 60 F CTGGAATAAACTGGATTTTCAACG
R TCAGGGAGGCAGCCATAGA
Arginase 1 61 F TTATCGGAGCGCCTTTCTCAA
R TGGTCTCTCACGTCATACTCTGT
CCL2 58 F AGGTCCCTGTCATGCTTCTG
R TCTGGACCCATTCCTTCTT
IL-1β 61 F TCCTTGTGCAAGTGTCTGAAGC
R ATGAGTGATACTGCCTGCCTGA
iNOS 60 F GGCAAACCCAAGGTCTACGTT
R TCGCTCAAGTTCAGCTTGGT
TNF-α 58 F GCCTCTTCTCATTCCTGCTT
R CTCCTCCACTTGGTGGTTTG
IL-12P40 60 F GACATCATCAAACCAGACCCGCC
R GCCTTTGCATTGGACTTCGGT
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above) or cell viability using AlamarBlue® Assay
(Thermo Fisher Scientific) following the manufac-
turer’s instructions.
Phagocytosis assay
B6M7 microglial cells in 96-well plates (10,000/well)
were treated with different concentrations of STF31for
24 h. The pHrodo® Green S. aureus BioParticles® kit
(Thermo Fisher Scientific) was used to determine phago-
cytosis of microglia following the manufacture’s instruc-
tions. The fluorescence intensity was quantified using a
plate reader (FLUOstar Omega microplate reader) at
485 nm (Excitation)/530 nm(Emission).
TUNEL staining
Cells and tissues were fixed in 2% paraformaldehyde
(PFA, Agar Scientific Ltd., Cambridge, UK) for 10 min
or 2 h, respectively. Eyes were embedded in optimal
cutting temperature compound (OCT, Thermo Fisher
Scientific) and cryosectioned (Leica CM1950 cryostat,
UK). 14 μm thick cryosections were treated with 0.1%
Triton X-100 (Millipore) for 5 min at room temperature
followed by 3 washes with PBS. Samples were incubated
with TUNEL-MIX, followed by 5% TUNEL-Enzyme in
TUNEL Label (Roche). DNase I (50 U/μl,
Sigma-Aldrich) treated samples were used as positive
control. Negative controls were incubated with TUNEL
label only. The samples were mounted using Vectashield
medium with DAPI (Vector Laboratories Ltd., Peterbor-
ough, UK).
Light-induced retinal degeneration and STF31
administration in mice
C57BL/6 J (12-week old) mice were treated with 10 mg/
kg STF31 twice daily for 2 days, followed by once daily
for another 3 days. The vehicle dimethyl sulfoxide
(DMSO) treated mice were used as controls. Body
weight and electroretinography were measured on day 6,
and eyes collected for immunohistochemistry. Four mice
were used in each group.
The CX3CR1gfp/+ mice were treated as above with the
first injection received 1 day before light exposure. Mice
were dark-adapted for 16 h and pupils were dilated with
1% phenylephrine and 2.5% tropicamide (Chauvin, Essex,
UK) under dim light. Mice were anesthetized with keta-
mine (Vetoquinol UK Ltd., Buckingham, UK) and Rom-
pun (Bayer HealthCare, Kiel, Germany) and exposed to
a focal white light (50,000 lx) delivered by an otoscope
(1218AA, Karl Storz, Tuttlingen, Germany) for 10 min.
At the end of the STF31 treatment, clinical and immu-
nohistochemical investigations were performed. Five
mice were used in each group.
Spectral domain optical coherence tomography
Mice were anesthetized and pupils dilated as described
above. Viscotears Liquid Gel (Novartis Pharmaceuticals
Ltd., Surrey, UK) was used to moisture the cornea. OCT
images (30° field of view) were collected using Spectral
Domain Optical Coherence Tomography (SD-OCT,
Heidelberg Engineering Ltd., Hertfordshire, UK). Neu-
roretinal thickness was measured in the area approxi-
mately 1000 μm away from the edge of the optical disc.
Electroretinography
Scotopic electroretinography (ERG) was conducted in
12-week old WT C57BL/6 J mice before and after STF31
treatment using Espion Visual Electrophysiology system
(Diagnosys LLC, Cambridge, UK) as described previ-
ously [23]. Briefly, mice were anesthetized and pupils
dilated as above. The mouse was placed on the heat-pad
(38 °C). ERG was recorded using mouse corneal ERG
electrodes in response to single white light flash, deliv-
ered by a standard Ganzfeld Stimulator (Diagnosys
LLC). ERG signals were bandpass filtered between 0.3–
500 Hz (without notch filtering), amplified 500-fold and
digitized at 2 kHz using the CMGS-1 electrophysiology
system (Diagnosys LLC).
Retinal flat mount staining
Mouse eyes were fixed in 2% PFA at room temperature
for 2 h. The retinas were dissected as previously
described [24]. Samples were incubated with 1% Triton
X-100 in PBS for 4 h, and blocked by incubation with 1%
BSA. Retinal flatmounts were incubated with rabbit
anti-cone arrestin (Millipore, Watford, UK) at 4 °C
overnight, followed by Alexa Fluor 594-conjugated don-
key anti-rabbit IgG (Life Technologies Ltd., Paisley, UK)
for 2 h. Images were obtained by confocal microscopy
(Eclipse TE200-U, Nikon UK Ltd., Surry, UK). The Fiji
Image-J Software was used for image analysis.
Immunoblotting
Microglia were lysed in RIPA buffer with protease
inhibitor cocktails and phosphatase inhibitors (Sigma-
Aldrich). The protein concentration was determined by
BCA kit (Thermo Fisher Scientific). Fifty microgram
proteins were loaded on a 10% SDS-PAGE gel and
transferred to an Immobilon polyvinylidene difluoride
membrane (Millipore). The membranes were incubated
sequentially with 3–5 ml primary antibodies (Table 2) in
5% dried milk solution in TBS/T overnight at 4 °C. The
membranes were washed and incubated with horserad-
ish peroxidase (HRP)-conjugated secondary antibodies
(Agilent) for 1 h in the dark at room temperature. The
signal was detected by autoradiography using enhanced
chemiluminescence (Clarity™ Western ECL Blotting
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Substrates, BioRad). Densitometric analysis was per-
formed using ImageJ software.
Statistical analyses
Data were processed and analyzed by GraphPad Prism
Software and presented as mean ± SEM. Comparisons
between more than two groups were conducted using
one-way ANOVA followed Dunnett’s Multiple Compari-
son Tests. Probability values of < 0.05 were considered
significant.
Results
Characteristics of a newly established microglial cell line
B6M7 cells
Immunocytochemistry showed that the B6M7 cells
express CD45, CD11b, Iba-1, TMEM119, but not Olig2
(Fig. 1a-e). The majority of B6M7 and primary microglial
(PMG) cells were strong positive for TMEM119 (Fig. 1e,
f ), whereas negligible levels of TMEM119 were detected
in peritoneal macrophages (Fig. 1g). The macrophage
marker F4/80 was strongly expressed by peritoneal macro-
phages, but only weakly expressed by microglia including
BV2, B6M7 cells and PMG (Fig. 1h-k). Furthermore,
B6M7 and BV2 cells, but not peritoneal macrophages,
showed a strong response to ATP-induced chemotaxis
(Additional file 1: Figure S1). The results suggest that
B6M7 cells maintain characteristics of microglia.
Glucose transporter expression by microglial cells
To understand which glucose transporters control glu-
cose uptake in microglia, we examined the expression of
different GLUTs in BV2, B6M7, and primary microglia.
Initial conventional PCR detected the mRNA of GLUT1,
3, 4, 5, 6, 8, 9, 10, 12, and 13 in primary microglial cells
(data not shown). Real-time RT-PCR was then employed
to determine relative expression levels of GLUTs in
different microglial cells. Among the 10 detected
GLUTs, GLUT1 had the highest levels of expression
in BV2 (Fig. 2a), B6M7 (Fig. 2b) and primary microglia
(PMG, Fig. 2c) cells. GLUT3 was also expressed at high
levels in all types of microglial cells (Fig. 2a-c). The
expression levels of other GLUTs vary in different types of
microglial cells. For example, GLUT5 was expressed at
high levels in B6M7 cells (Fig. 2b), but at low levels
in primary microglia (Fig. 2c). The expression of
GLUT1 in B6M7, primary microglia (Fig. 2d) and in
vivo retinal microglia (Fig. 2e) was further confirmed
by immunostaining.
Increased GLUT-1 expression in inflammatory microglia
LPS + IFNγ treatment significantly upregulated the
expression of IL-1β, TNFα, CCL2, IL-12p40 and iNOS,
whereas IL-4 treatment increased the expression of
Arginase-1 in BV2 and B6M7 cells (Fig. 3a). In general,
B6M7 cells had higher levels of inflammatory gene ex-
pression following LPS + IFNγ stimulation compared to
BV2 cells (apart from IL-12p40, Fig. 3a). To understand
how glucose metabolism is related to microglial activa-
tion, glucose uptake was measured in naïve and acti-
vated microglial cells. M(LPS + IFNγ) microglia
consumed significantly higher amounts of glucose than
naïve and M(IL-4) microglia (Fig. 3b). In line with higher
levels of inflammatory cytokine expression, glucose up-
take was also significantly higher in B6M7 M(LPS +
IFNγ) cells compared with BV2 M(LPS + IFNγ) cells
(Fig. 3b). Real-time RT-PCR showed that only the ex-
pression of GLUT1 was significantly increased following
LPS + IFNγ stimulation (Fig. 3c). None of the GLUTs
were affected by IL-4 treatment (Fig. 3c). The upregula-
tion of GLUT1 by LPS + IFNγ treatment was further
confirmed at the protein level by Western Blot
(Fig. 3d-e).
Bioenergetic profiles in active microglia
The bioenergetic profiles of microglial cells were exam-
ined using the Seahorse XFe96 Analyser. The basal OCR,
ATP production and maximal respiration of M(LPS +
IFNγ) microglia was significantly reduced in both BV2
(Fig. 4a-d) and B6M7 (Fig. 4e-h) cells compared to naïve
microglia. IL-4 treatment slightly increased the basal OCR
and ATP production in BV2 (Fig. 4b, c) but not in B6M7
cells (Fig. 4f, g). The glycolysis and glycolytic capacity were
significantly increased following LPS + IFNγ but not
IL-4 stimulation in both BV2 (Fig. 5a-c) and B6M7
Table 2 Antibodies used for western blot
Targets Primary Antibody (Company; Dilution) Secondary Antibody (Dilution)
β-actin Mouse Monoclonal (Santa Cruz, 1:10000) Polyclonal Rabbit anti-mouse HPR (1:5000)
GLUT1 Rabbit Polyclonal (Thermo Fisher, UK; 1:1000) Polyclonal Goat anti-Rabbit HPR (1:5000)
GLUT4 Rabbit Polyclonal (Thermo Fisher, UK; 1:1000) Polyclonal Goat anti-Rabbit HPR (1:5000)
GLUT5 Rabbit Polyclonal (Thermo Fisher, UK; 1:1000) Polyclonal Goat anti-Rabbit HPR (1:5000)
GLUT9 Rabbit Polyclonal (Millipore Merck, UK; 1:5000) Polyclonal Goat anti-Rabbit HPR (1:5000)
GLUT10 Rabbit Polyclonal (Thermo Fisher, UK; 1:800) Polyclonal Goat anti-Rabbit HPR (1:5000)
GLUT12 Rabbit Polyclonal (Antibodies-online; 1:2000) Polyclonal Goat anti-Rabbit HPR (1:5000)
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cells (Fig. 5d-f ). Our results suggest that M(LPS +
IFNγ) microglia are fueled predominately by glycolysis
rather than mitochondrial respiratory phosphorylation.
The role of GLUT1 in microglial metabolism
Having shown that M(LPS + IFNγ) microglia are fueled
by the glycolytic pathway and GLUT1 is highly
expressed in these cells, we then examined the effect of
a GLUT1 specific inhibitor STF31 [25] on microglial ac-
tivation. STF31 dose-dependently suppressed glucose
uptake in B6M7 cells (Fig. 6a) without affecting cell via-
bility (Additional file 1: Figure S2A, B). 5 μM of STF31
significantly reduced glucose uptake in naïve, M(LPS +
IFNγ) and M(IL-4) microglial cells (Fig. 6b). The expres-
sion of GLUT1 and other GLUTs was not affected by
STF31 treatment (Additional file 1: Figure S2C-E). This
concentration of STF31 was, therefore, used in the rest
of the in vitro studies.
Glycolysis stress test in naïve (Fig. 6c), M(LPS + IFNγ)
(Fig. 6d) and M(IL-4) (Fig. 6e) cells showed that STF31
(5 μM) significantly reduced glycolysis (Fig. 6f ) and
glycolytic capacity (Fig. 6g), suggesting shutting-down of
the glycolytic pathway by STF31.
The basal OCR and ATP production was not
affected by STF31 in naïve microglia in Mito stress
assay (Fig. 7a, d-e). However, the spare respiratory
capacity (SRC) was significantly reduced following
STF31 treatment (Fig. 7f ), suggesting that glucose is
needed for maximal respiration but not for basal res-
piration and ATP production in naïve microglia.
In M(LPS + IFNγ) microglia, the treatment of STF31
significantly increased basal OCR, ATP production, and
SRC (Fig. 7b, d-f ), suggesting re-programming of the
metabolic pathway towards mitochondrial respiration.
Interestingly, STF31 treatment significantly decreased
basal OCR, ATP production and SRC in M(IL-4) micro-
glia (Fig. 7c, d-f ), indicating that mitochondrial respir-
ation in these cells is fueled partially by glucose.
Mitochondrial superoxide production (measured by
MitoSOX Red) did not change following LPS + IFNγ
or IL-4 stimulation in B6M7 and primary microglia
(Fig. 7g, h). Blocking glucose uptake by STF31 signifi-
cantly increased mitochondrial superoxide in M(IL-4)
microglia (Fig. 7g, h), suggesting that Glut-1 mediated
glucose metabolism is important to maintain mito-
chondrial membrane potential in these cells.
Taken together, our results suggest that GLUT1
critically control glucose uptake in microglial cells
and blocking GLUT1 with STF31 switches the
bioenergetic pathway from glycolysis to OXPHOX in
M(LPS + IFNγ) microglia but reduces OXPHOX in
M(IL-4) microglia.
Fig. 1 Immunocytochemistry of B6M7 cells. a-d B6M7 cells were stained for CD45 (a), CD11b (b), Iba1 (c), and Olig2 (d). e-g TMEM119 expression
(red) in B6M7, primary microglia (PMG) and peritoneal macrophages (MФ). (h-k) F4/80 expression (green) in BV2, B6M7, PMG and peritoneal
macrophages. Cell nuclei were stained with DAPI. All samples were examined by confocal microscopy. Scale bar = 25 μm
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The effect of STF31 on microglial phagocytosis and
activation
The phagocytosis of S.aureus bioparticles by B6M7 and
primary microglia was dose-dependently suppressed by
STF31 (Fig. 8a). Real time RT-PCR showed that STF31
treatment significantly reduced the expression of TNFα,
IL-1β, IL-6, iNOS, and CCL2 in M(LPS + IFNγ) cells
(Fig. 8b). The production of TNFα, CCL2, RANTES,
IL-6, and NO was also significantly reduced following
STF31 treatment (Fig. 8c). Interestingly, the treatment also
suppressed IL-4-induced arginase-1 expression (Fig. 8b).
Intracellular ROS was significantly increased following
LPS + IFNγ treatment in both B6M7 and primary micro-
glia, and the increment was prevented by STF31 treat-
ment (Fig. 8d).
In vivo effect of STF31 on microglial activation and retinal
degeneration
Uncontrolled microglial activation is known to contrib-
ute to photoreceptor death in the mouse model of
light-induced retinal degeneration [26]. Therefore, we
further tested the effect of STF31 on microglial activa-
tion in this model. Intraperitoneal injection of STF31
(10 mg/kg, for 5 days) in normal mice did not affect their
body weight, behavior, and ERG responses (Additional
file 1: Figure S3A, B). The treatment did not induce any
retinal cell death (Additional file 1: Figure S3C).
Massive photoreceptor loss (Fig. 9a-b, e) and micro-
glial activation (Fig. 9f-g, j) were observed 4 days after
light exposure. STF31 treatment improved photorecep-
tor survival and reduced microglial activation (Fig. 9).
The treatment with vehicle (DMSO) did not show any
protective effect (Fig. 9). SD-OCT examination showed
improvement in both retinal structure and thickness,
particularly the outer retinal layers (from ONL to IS/OS,
Additional file 1: Figure S4E, G) following STF31 treat-
ment (Additional file 1: Figure S4).The treatment did not
significantly improve the thickness of the inner retina
(from NFL/GL to OPL, Additional file 1: Figure S4E, F).
Discussion
Glucose is essential for microglial survival and function.
A previous study has shown that glucose depletion led
to 74% microglia death within 30 min and 98% after 48 h
[27]. Here, we show that glucose uptake in microglia is
mediated predominately by GLUT1. Importantly, we show
that glycolysis in inflammatory M(LPS + IFNγ) microglia
also relays on GLUT1-mediated glucose uptake, and
blocking GLUT1 re-programmed proinflammatory micro-
glia from glycolysis to OXPHOX, suppressed microglial
Fig. 2 GLUT expression in microglial cells. Quantitative RT-PCR analysis of GLUT-1, 3, 4, 5, 6, 7, 8, 9, 10, 12 and 13 in BV2 (a), B6M7 (b) and primary
microglial (PMG, c) cells. Data were expressed as relative expression of GLUTs against β-actin. Mean ± SEM, n = 6. d Confocal images showing
GLUT1 (red) and F4/80 expression in B6M7 and primary microglia. Scal bar = 50 μm. e Retinal section from CX3CR1GFP/+ mice was stained
for GLUT1 (red) and imaged by confocal microscopy. Arrow indictes a GFP positive microglia expressing GLUT1. Scale bar = 20 μm
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activation and reduced light-induced retinal degeneration.
Our data also show that GLUT1-mediated glucose metab-
olism is critically involved in mitochondrial respiration in
M(IL-4) microglia. Our results highlight the importance
of GLUT1-mediated glycolysis in microglial function
under pathophysiological conditions.
Naïve microglia are fueled by both glycolysis and mito-
chondrial oxidative phosphorylation. Previous studies
have shown that microglia express GLUT3, GLUT4 [28],
and GLUT5 [29, 30]. GLUT1 was reported to be
expressed in oligodendrocytes and astrocytes but not
microglia [31]. In the current study, we detected 13
GLUTs in murine primary microglia, BV2, and a newly
established murine microglial cell line B6M7 cells. Sur-
prisingly, we found that GLUT1 was expressed at the
highest level among other GLUTs, and the expression of
GLUT1 was further enhanced following LPS + IFNγ
stimulation. This is in line with the metabolic
re-programming of the cells towards anaerobic glycoly-
sis. The expression of other GLUTs was not affected by
LPS + IFNγ treatment. Our results suggest that GLUT1
critically controls glucose uptake and the glycolytic
Fig. 3 Changes in glucose uptake and GLUT expression during microglial activation. BV2 and B6M7 cells were untreated or treated with
LPS + IFNγ or IL-4 for 24 h. Cells were then processed for real-time RT-PCR (a, c), glucose uptake (b) or Western blot (d). a The expression of
inflammatory mediators in naïve, LPS + IFNγ or IL-4 treated BV2 and B6M7 cells. N = 3, *, P < 0.05; **, P < 0.01, ***P < 0.001. b Glucose uptake in
non-treated control, LPS + IFNγ or IL-4 treated BV2 and B6M7 cells. N = 3, *, P < 0.05. c mRNA expression of different GLUTs in control, LPS + IFNγ
or IL-4 treated B6M7 cells. N = 3, ***, P < 0.001 compared to naïve microglia. d Western blot showing GLUT1, 4, 5, 9, 10, 12 in control (naïve), LPS
+ IFNγ treated, and IL-4 treated B6M7 cells. β-actin was used as housekeeping control. e Densitometric analysis showing GLUT expression related
to control in LPS + IFNγ or IL-4 treated B6M7 cells. N = 3, ***, P < 0.001 compared to naïve microglia
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pathway in microglial cells, particularly under inflamma-
tory conditions.
Phagocytosis is important for microglia to maintain CNS
homeostasis. We show that blocking GLUT1-mediated
glucose uptake reduced glycolysis (Fig. 6) and suppressed
phagocytosis (Fig. 8a). Our results suggest that GLUT1-
mediated glycolysis is critically involved in microglial
phagocytosis. This is in line with our recent observation in
the phagocytic function of peritoneal macrophages [32].
Blocking GLUT1 in naïve microglia did not affect
mitochondrial basal respiration and ATP production, but
significantly reduced SRC (Fig. 7f). SRC is important for
Fig. 5 Glucose metabolism in different types of microglial cells. BV2 and B6M7 cells were untreated (control), or treated with LPS + IFNγ or IL-4
for 24 h. a, d Representative ECAR profiles of BV2 (a) and B6M7 (d) cells following glucose, oligomycin and 2-DG treatments in the Glycolysis
Stress assay. b, e Changes in basal ECAR in LPS + IFNγ treated and IL-4 treated microglial cells compared to naïve microglia. c, f Changes in
glycolytic capacity in LPS + IFNγ treated and IL-4 treated cells compared to naïve microglia. Mean ± SEM, n = 3 repeated experiments,
**P < 0.01, ***P < 0.001
Fig. 4 Mitochondrial respiration in different types of microglial cells. BV2 and B6M7 cells were untreated (naïve), or treated with LPS + IFNγor IL-4
for 24 h. The cells were then subjected to Mito Stress Test. The OCR was measured sequentially under basal conditions, following inhibition of
ATP synthase (with oligomycin), uncoupling the electron transporter chain (ETC) with FCCP, and blocking complex I and III with rotenone and
antimycin A. a, e Representative OCR profiles of BV2 (a) and B6M7 (e) naïve, LPS + IFNγ- or IL-4-treated cells. b, f Changes in basal OCR in LPS +
IFNγ treated and IL-4 treated cells compared to naïve microglia. c, g Changes in ATP production in LPS + IFNγ- and IL-4-treated microglial cells
compared to naïve microglia. d, h Changes in maximal respiration in LPS + IFNγ- and IL-4-treated microglial cells compared to naïve microglia.
Mean ± SEM, n = 3 repeated experiments, **P < 0.01, ***P < 0.001
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cells to deal with stress conditions when additional energy
is required. Our results suggest that GLUT1-dependent
glycolysis may provide reserved energy to microglia under
stress conditions for survival and function.
Microglial activation is a necessary and beneficial re-
sponse to CNS insults. However, uncontrolled microglial
activation contributes critically to the pathogenesis of vari-
ous neurodegenerative diseases [33] through the release of
excessive amount of inflammatory mediators. Recent
studies have shown that M1-type proinflammatory micro-
glia are fueled by anaerobic glycolysis [18]. Previous stud-
ies have shown that the glycolysis pathway provides
essential building blocks such as amino acids and fatty
acids for the assembling of inflammatory mediators in
macrophages [34–36] and effector T helper cells [37–39].
Our data and that of others [18] suggest that inflamma-
tory microglia are also fueled by the glycolytic pathway.
A recent study using dual tracer positron emission tom-
ography has shown that following cerebral ischemia, neu-
rons and astrocytes died from oxygen deficiency but
immune cells metabolized glucose non-oxidatively [40],
suggesting that they are likely supported by anaerobic gly-
colysis at the ischemic inflammatory site. The immune
cells at the lesion sites may consist of resident microglia
and infiltrating leukocytes. Shifting immune cell metabol-
ism towards anaerobic glycolysis in an environment in
Fig. 6 The effect of STF31 on microglial glucose metabolism. a Naïve B6M7 cells were treated with different concentrations of STF31 for 24 h.
Glucose uptake was then conducted. n = 3, *, P < 0.05; **, P < 0.01; ***, P < 0.001, One-way ANOVA with Dunnett’s Multiple post-test. b
Glucose uptake in naïve (M0), LPS + IFNγ treated and IL-4 treated microglial cells with or without 5 μM STF31 pre-treatment for 24 h. n =
3, **, P < 0.01; ***, P < 0.001, two-way ANOVA with Bonferroni post-test. c-e Representative ECAR profiles in naïve (c), LPS + IFNγ treated
(d), and IL-4 treated (e) microglia with or without 5 μM STF31. f The effect of STF31 on glycolysis of M0, M(LPS + IFNγ), and M(IL-4) B6M7
microglial cells. g The effect of STF31 on glycolytic capacity of naive, LPS + IFNγ treated and IL-4 treated B6M7 cells. Mean ± SEM, n = 3
repeated experiments, *P < 0.05; **P < 0.01; ***P < 0.001
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which the supply of oxygen and nutrients is restricted
requires the upregulation of the facilitators of glucose
transport. Our results suggest that inflammatory microglia
upregulate GLUT1 to facilitate glucose uptake.
Using STF31, we show that when GLUT1-mediated
glucose uptake is blocked in inflammatory microglia, the
metabolic pathway can be further re-programmed
towards OXPHOX. Consequently, the expression of in-
flammatory genes and the production of inflammatory
mediators are reduced. It is important to note that al-
though STF31 dose-dependently reduced glucose uptake
in microglia, it did not completely block glucose uptake
(Fig. 6a). 5 μm STF31 reduced glucose uptake from 85
pmol to 25 pmol in M(LPS + IFNγ) microglia (Fig. 6b),
and glycolysis was not diminished (Fig. 6c-e). The results
suggest that apart from GLUT1, other GLUTs also facili-
tate glucose uptake in microglia. This may explain why
microglia did not undergo cell death after STF31 treat-
ment as seen in some tumor cells [41].
Another important observation of this study is the re-
quirement of glucose in mitochondrial OXPHOX in al-
ternatively active M(IL-4) microglia. Previous studies
have shown that the M(IL-4) microglia are supported
by an intact tricarboxylic acid (TCA) cycle and en-
hanced mitochondrial OXPHOX [18]. However, the
fuel source of OXPHOX in M(IL-4) microglia remains
elusive. We show that when glucose uptake is restricted
by STF31, mitochondrial basal respiration, ATP pro-
duction and SRC were all significantly reduced, whereas
mitochondrial superoxidate is increased in M(IL-4)
Fig. 7 The effect of STF31 on microglial mitochondrial respiration. B6M7 cells were incubated with 5 μM STF31, and then stimulated with LPS +
IFNγ or IL-4. The cells were then subjected to Mito Stress assay (a-f) or MitoSOX Red assay (g, h). a-c Representative OCR profiles in naïve (a),
M(LPS + IFNγ) (b), and M(IL-4) (c) microglia with or without 5 μM STF31. d The effect of STF31 on microglial basal respiration of naïve, M(LPS +
IFNγ), and M(IL-4) microglial cells. e The effect of STF31 on ATP production of naive, M(LPS + IFNγ), and M(IL-4) microglial cells. f The effect of
STF31 on spare respiratory capacity of naive, M(LPS + IFNγ), and M(IL-4) microglial cells. g, h The effect of STF31 on the production of
mitochondrial superoxidate in naive, LPS + IFNγ, IL-4 treated B6M7 (g) and primary microglia (PMG, h). Mean ± SEM, n = 3 repeated experiments,
*, P < 0.05; **P < 0.01; ***P < 0.001
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microglia. Previously, fatty acids were shown to support
mitochondrial oxidative metabolism in M(IL-4) macro-
phages [42]. Recent studies suggest that glucose can
also fuel OXPHOX in M(IL-4) macrophages [43–45].
Our results suggest that mitochondrial respiration in
M(IL-4) microglia is at least partially fueled by glucose.
The newly established microglial cell line B6M7 cells
were used in this study. The cells express high levels of
Fig. 8 The effect of STF31 on microglial phagocytosis, cytokine expression/secretion and intracellular reactive oxygen spececis production. a
B6M7 cells and primary microglia (PMG) were incubated with 5 μM STF31 for 24 h. Phagocytosis was performed using the pHrodo Green S.
aureus BioParticles. Inserted images showing green fluorescence from phagocytosed S. aureus bioparticles in different groups of cells. Mean ±
SEM, n = 3 (repeated experiments), *P < 0.05; **P < 0.01; ***P < 0.001. One-way ANOVA with Tukey’s Multiple Comparison Test. b-d B6M7 cells
were incubated with 5 μM STF31 for 24 h followed by LPS + IFNγ or IL-4 stimulation. The mRNA expression of TNFα, IL-β, IL-6, iNOS, CCL2 and
arginase-1 was measured by real-time RT-PCR (b). c The production of TNFα, CCL2, RANTES, and IL-6 was measured by CBA, and NO production
was determined by Griess Assay. d The effect of STF31 on intracellular reactive oxygen species (ROS) production in naive, LPS + IFNγ, IL-4 treated
B6M7 and primary microglia (PMG) meased by CellRox Green assay. Mean ± SEM, n = 3 repeated experiments, **P < 0.01;
***P < 0.001; ****P < 0.0001
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TMEM119 (a microglial-specific marker) but low levels
of F4/80 (a typical macrophage marker). ATP is known
to induce chemotaxis in microglia but not macrophage
through Gi/o-coupled P2Y receptors [46]. The B6M7
cells, but not peritoneal macrophages had a strong
chemotactic response to ATP stimulation. Our results
suggest that B6M7 cells phenotypically and functionally
resemble microglia but not macrophages. Lineage tra-
cing study will help to confirm the true identity of the
cells. The B6M7 cells and BV2 cells have some func-
tional differences. For example, ATP-induced chemo-
taxis is significantly higher in B6M7 cells than that in
BV2 cells. The LPS + IFNγ-induced inflammatory gene
expression was also significantly higher in B6M7 cells
than that in BV2 cells. The B6M7 cells could be an use-
ful additional resource in neuroimmunology studies.
Conclusion
Glucose uptake in microglia is dominated by GLUT1.
Under inflammatory conditions, microglia further upreg-
ulate GLUT1 to facilitate glucose uptake and promote
anaerobic glycolysis. Blocking GLUT1 is an effective
approach to re-program the metabolic pathway and
control microglial activation and neurodegeneration. As
glucose uptake in neurons is mediated predominately by
GLUT3 [20], blocking GLUT1 may not only suppress
microglial activation, but also increase available nutri-
ents to neurons, particularly in the inflamed ischemic
CNS when glucose supply is restricted. Since GLUT1 is
expressed by many other cells (e.g., astrocytes, Muller
cells, photoreceptors, endothelial cells) in the retina and
it critically controls glucose uptake to CNS parenchyma
at the blood-brain-barrier [20], cell-specific inhibition of
GLUT1 (e.g., via CX3CR1 or CFSR promoters) would be
an ideal approach to control microglial activation and
neuroinflammation.
Additional file
Additional file 1: Figure S1. ATP-induced microglial migration using
the transwell assay. B6M7, BV2 cells and peritoneal macrophages (3,000/
well) were seeded into the upper chamber in a trans-well culture system
for 16h. 100 μM ATP was then added into the bottom chamber. 3 hours
later, cell numbers in bottom chambers were counted. Mean ±SEM, N=6
***P<0.001. Figure S2. The effect of STF31 on microglial cells. (A) B6M7
cells were treated with different concentrations of STF31 and cell viability
was assessed by AlamarBlue 24 h and 48 h after treatment. N=3. (B)
Representative images and quantifications of TUNEL assay in naïve, M(LPS
+IFNγ), and M(IL-4) microglia with or without 5 μM STF31. Arrow shows a
TUNEL-positive cell. Scale bar = 50 μm. N=3. (C, D) RT-PCR (C) and Western
Blot (D) showing the expression of GLUT1 in B6M7, with or without 5 μM
STF31. (E) RT-PCR showing the expression of GLUTs in B6M7 microglial cells,
with and without 5 μM STF31. RT-PCR and western blot data were
expressed as relative expression against β-actin (n=3). Mean ±SEM.
Figure S3. The effect of STF31 on mouse retina. Mice were injected
intraperitoneally with STF31 (10 mg/kg) for 5 days. Four mice were used. (A)
Representative ERG responses at day 0 (before the onset of STF31 treat-
ment) and day 4. (B) Quantitative analysis of a-wave and b-wave amplitudes,
before (day 0) and after (day 4) STF31 treatment. (C, D) Representative
images (C) and quantifications (D) of TUNEL assay in control and STF31-
treated mice. Scale bar = 25 μm. Figure S4. The effect of STF31 on retinal
thickness in light-induced retinal degeneration. CX3CR1gfp/+ mice were
exposed to 50,000 lux focal white light for 10 minutes with daily STF31 or
Fig. 9 The effect of STF31 on light-induced photoreceptor degeneration and microglial activation. CX3CR1gfp/+ mice were exposed to 50,000 lx
focal white light for 10 min with daily STF31 or vehicle (DMSO) treatment. Eyes were collected 4 days after light exposure. a-d Representative
confocal images showing cone arrestin-positive cells in control (a), light-exposed (b), light + STF31 (c) and light + DMSO (d) mice. e Graph
showing the number of cone photoreceptors in different groups of mice. f-i Representative confocal images showing GFP-positive retinal
microglia in normal (f), light-exposed (g), light + STF31 (h) and light + DMSO (I) mice. j Graph showing the average number of cross points of
microglia in different groups of mice. Mean ± SEM. A minimum of 6 images was taken from each retina. Full control, n = 4 mice, n = 6 mice in
other groups. * P < 0.05; ***P < 0.001. Scale bar: 50 μm
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vehicle (DMSO) treatment. (A-D) Representative images from each group of
mice. (E) Bar graph showing the average thickness of the entire neuronal
retina (from nerve fiber/ganglion layer to inner/outer segments layer, illus-
trated in A) in each group. (F) Bar graph showing the thickness of the inner
retina (from nerve fiber/ganglion layer to inner plexiform layer, illustrated in
A). (G) Bar graph showing the thickness of the outer retina (from outer nu-
clear to inner/outer segments, illustrated in A). Full control: N=4 mice, N=6
mice in other groups. **P < 0.01; ***P< 0.001. (DOCX 1656 kb)
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